Table 18. Phenotypic patterns and numbers of pathological T-cells detected with the final version of the EuroFlow T-CLPD panel (n=67).
|
No of T-cells |
|||
|---|---|---|---|
| Diagnostic groupa | Aberrant T-cellsb (no. of cases/total cases) | % of T-cells (from WBC)c | No of T-cellsd ( × 103/μl) |
| Healthy adult donors (n=11) | 0/11 | CD4+/CD8−: 12.3 (7.4–21.8) | 700 (400–1900) |
| CD8hi/CD4−: 7.2 (2.8–14.4) | 400 (170–1000) | ||
| CD4−/CD8−/lo: 0.6 (0.2–3.7) | 50 (10–200) | ||
| CD4+/CD8hi: 0.34 (0.0–2.1) | 20 (7–100) | ||
| Clonal expansions of CD4+ T-cellse (n=34) | |||
| Sézary syndrome (n=9) | 9/9 | 24 (4.4–88.7) | 3560 (170–5300) |
| T-PLL (n=5) | 5/5 | 90 (61–96) | 214 000 (63 000–528 000) |
| ATLL (n=4) | 4/4 | 82 (39–85) | 23 600 (3200–34 900) |
| CD4+ LGL (n=4) | 4/4 | 25 (10–60) | 2300 (1500–3200) |
| AITL (n=2) | 2/2 | 5.6 (3–8.3) | 1100 |
| PTCL-NOS (n=10) | 10/10 | 14 (3.3–65) | 3000 (1900–6100) |
| Clonal expansions of CD8hi T-cells (n=11) | |||
| T-LGL (n=10) | 9/10 | 27 (1–56) | 1500 (110–9500) |
| CD8hi PTCL-NOS (n=1) | 1/1 | 17 | 6010 |
| Clonal expansions of CD4−/CD8−/lo T-cells (n=11) | |||
| TCRγδ+ T-LGL (n=9) | 8/9 | 19 (1.3–33) | 1500 (30–5900) |
| TCRγδ+ hepatosplenic T-cell lymphoma (n=1) | 1/1 | 24 | ND |
| TCRαβ+ T-CLPD (n=1) | 1/1 | 75 | NA |
Abbreviations: AITL, angioimmunoblastic T-cell lymphoma; ATLL, adult T-cell leukemia–lymphoma; BM, bone marrow; CLPD, chronic lymphoproliferative disorders; LGL, large granular lymphocyte leukemia; NA, not applicable; ND, not available; PB, peripheral blood; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified; TCR, T-cell receptor; T-PLL, T-cell prolymphocytic leukemia; WBC, white blood cells.
A total of 67 cases was evaluated, which corresponded to 59 PB, 7 BM and 1 ascitic fluid sample.
According to previously reported studies (References78, 243, 245, 254, 258, 260, 261, 262, 263, 264, 265,266).
Results expressed as median % of T-cells from WBC (range). For the different patient groups, only data from the expanded/ aberrant T-cell population is shown.
Results expressed as median absolute number of circulating T-cells × 103/μl (range) for the PB samples analyzed; for the different patient groups, only data from the expanded/aberrant T-cell populations are shown.
Regardless of CD8 expression (either negative or dimly positive).